Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr 15;19(R1):R98-R102.
doi: 10.1093/hmg/ddq148. Epub 2010 Apr 26.

Huntington's disease: progress toward effective disease-modifying treatments and a cure

Affiliations
Review

Huntington's disease: progress toward effective disease-modifying treatments and a cure

Carl D Johnson et al. Hum Mol Genet. .

Abstract

Huntington's disease (HD) is caused by a dominant mutation in HTT, the HD gene. This discovery opens possibilities for treatment based on silencing of the disease-causing allele or with compounds that reduce the production of disease-causing mRNA and/or protein. Although additional developments are needed related to the delivery of gene silencing and discovery and development of drugs that reduce disease-causing gene products, these treatments are predicted to be effective since they act by reducing the source of toxicity. The identification of therapies that act by blocking toxicity is conceptually more complicated, as this requires an accurate understanding of the cellular location and the specific molecular dysfunctions that cause the phenotypes of HD, which is not yet available. Though challenges remain, significant progress has been made. Effective disease-modifying treatments will soon be tested and may lead to disease-altering therapies.

PubMed Disclaimer

References

    1. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005;25:157–163. doi:10.1523/JNEUROSCI.3842-04.2005. - DOI - PMC - PubMed
    1. Douaud G., Behrens T.E., Poupon C., Cointepas Y., Jbabdi S., Gaura V., Golestani N., Krystkowiak P., Verny C., Damier P., et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage. 2009;46:958–966. doi:10.1016/j.neuroimage.2009.03.044. - DOI - PubMed
    1. Rosas H.D., Lee S.Y., Bender A.C., Zaleta A.K., Vangel M., Yu P., Fischl B., Pappu V., Onorato C., Cha J.H., et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical ‘disconnection. Neuroimage. 2010;49:2995–3004. doi:10.1016/j.neuroimage.2009.10.015. - DOI - PMC - PubMed
    1. Weaver K.E., Richards T.L., Liang O., Laurino M.Y., Sami A., Aylward E.H. Longitudinal diffusion tensor imaging in Huntington's Disease. Exp. Neurol. 2009;16:525–529. - PMC - PubMed
    1. Dalrymple A., Wild E.J., Joubert R., Sathasivam K., Bjorkqvist M., Petersen A., Jackson G.S., Isaacs J.D., Kristiansen M., Bates G.P., et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007;6:2833–2840. doi:10.1021/pr0700753. - DOI - PubMed

Publication types